Empirico is a biotechnology startup that leverages human genetics to develop new medicines. The company operates in the pharmaceutical industry, serving clients that include healthcare providers and patients in need of novel therapeutic interventions. Empirico's business model is centered around the use of large biological datasets, human genetics, and programmable biology to discover and develop new drug targets.

The company's team of physicians, biologists, chemists, data scientists, and drug developers work together to understand the role of genes and proteins in health and disease. They do this by analyzing genetic data and health information from millions of individuals. This approach, which the company refers to as "leveraging experiments of nature," is aimed at improving the success rate of pharmaceutical discovery and development.

Empirico's Precision Insights Platform™ is a key part of its operations. This platform, which was specifically built for target discovery, combines expert data curation, customized data models, and proprietary algorithms. It allows the company's scientists to generate, interrogate, and prioritize high-confidence therapeutic hypotheses. The platform is built on vast amounts of data from thousands of studies and millions of individuals, making it one of the largest datasets of its kind in the world.

The company also works with partners and collaborators, such as AbCellera, to validate therapeutic hypotheses and find the best approach to translate them into therapeutic targets. This involves conducting experiments to understand how genetic variation impacts disease risk and how a therapeutic modality could be programmed to mimic or interfere with that mechanism.

In terms of revenue, Empirico likely makes money through the development and sale of new drugs, as well as through strategic partnerships and collaborations.

Keywords: Biotechnology, Human Genetics, Pharmaceutical Industry, Therapeutic Interventions, Data Analysis, Precision Insights Platform™, Drug Development, Genetic Variation, Disease Risk, Strategic Partnerships.